Android app on Google Play

Sanofi (SNY), Regeneron (REGN) Receive EC Marketing Approval for ZALTRAP

February 6, 2013 6:15 AM EST Send to a Friend
Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has granted marketing authorization in the European Union for ZALTRAP 25mg/ml concentrate for solution for infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen. This decision was based on the efficacy and safety results of the VELOUR Phase 3 trial.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment